SCHEMBL4351105

SCHEMBL4351105

Nc1nc(SCc2cc([N+](=O)[O-])ccc2O)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 17/20 1.00
LMNA P02545 1/20 0.78
RAB9A P51151 1/20 0.78
CYP3A4 P08684 1/20 0.78
PKM P14618 1/20 0.78
HPGD P15428 1/20 0.78
SMN1; SMN2 Q16637 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1763081 0.88 SLC29A1 (1.00) SLC29A1LMNARAB9ACYP3A4PKM
SCHEMBL20579724 0.88 SLC29A1 (1.00) SLC29A1LMNARAB9ACYP3A4PKM
SCHEMBL29784689 0.88 SLC29A1 (1.00) SLC29A1LMNARAB9ACYP3A4PKM
SCHEMBL1322160 0.88 SLC29A1 (1.00) SLC29A1LMNARAB9ACYP3A4PKM
SCHEMBL6761745 0.78 SLC29A1 (1.00) SLC29A1LMNARAB9ACYP3A4PKM
SCHEMBL31462888 0.78 SLC29A1 (1.00) SLC29A1LMNARAB9ACYP3A4PKM
SCHEMBL30614562 0.78 SLC29A1 (0.71) SLC29A1LMNARAB9ACYP3A4PKM
SCHEMBL9350420 0.76 SLC29A1 (0.83) SLC29A1LMNARAB9ACYP3A4PKM
SCHEMBL6905077 0.76 SLC29A1 (0.83) SLC29A1LMNARAB9ACYP3A4PKM
SCHEMBL9346470 0.76 SLC29A1 (0.83) SLC29A1LMNARAB9ACYP3A4PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12054768-B2 Methods for detecting agglutination and compositions for use in practicing the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-08-06 US disclosed
EP-4123031-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME The Regents of The University of California (US) 2023-01-25 EP disclosed
EP-3283638-B1 METHODS FOR DETECTING AGGLUTINATION AND USE OF KITS IN PRACTICING THE SAME UNIV CALIFORNIA (US) 2022-06-08 EP disclosed
US-20210403978-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-30 US disclosed
US-11149296-B2 Methods for detecting agglutination and compositions for use in practicing the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-10-19 US disclosed
US-20200232005-A1 Methods of Producing and Using Single-Stranded Deoxyribonucleic Acids and Compositions for Use in Practicing the Same TAKARA BIO USA, INC. 2020-07-23 US disclosed
US-10584363-B2 Methods of producing and using single-stranded deoxyribonucleic acids and compositions for use in practicing the same TAKARA BIO USA, INC. (US) 2020-03-10 US disclosed
US-20180100181-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2018-04-12 US disclosed
EP-3283638-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME The Regents of The University of California (US) 2018-02-21 EP disclosed
CN-107614699-A Method for detecting agglutination and composition for practicing the method 加利福尼亚大学董事会 2018-01-19 CN disclosed
US-20170349927-A1 METHODS OF PRODUCING AND USING SINGLE-STRANDED DEOXYRIBONUCLEIC ACIDS AND COMPOSITIONS FOR USE IN PRACTICING THE SAME TAKARA BIO USA, INC. 2017-12-07 US disclosed
WO-2016168711-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-10-20 WO disclosed
US-20090280153-A1 electrical devices, anti-scarring agents, and therapeutic compositions ANGIOTECH INTERNATIONAL AG (CH) 2009-11-12 US disclosed
US-20090226500-A1 SUTURES AND ANTI-SCARRING AGENTS ANGIOTECH PHARMACEUTICALS, INC (CA) 2009-09-10 US disclosed
EP-1978930-A2 SUTURES AND ANTI-SCARRING AGENTS Angiotech Pharmaceuticals, Inc. (CA) 2008-10-15 EP disclosed
WO-2007089878-A2 SUTURES AND ANTI-SCARRING AGENTS ANGIOTECH PHARMACEUTICALS, INC. (CA) 2007-08-09 WO disclosed
WO-2006121522-A2 IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS ANGIOTECH INTERNATIONAL AG (CH) 2006-11-16 WO disclosed
WO-2006121518-A2 ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS ANGIOTECH INTERNATIONAL AG (CH) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090226500-A1 SUTURES AND ANTI-SCARRING AGENTS COL1A1, COL2A1, COL14A1 SLC29A1 4272/4885LMNA 844/4885RAB9A 2683/4885
US-20090280153-A1 electrical devices, anti-scarring agents, and therapeutic compositions GAP43, TNNC1, GJB2 SLC29A1 3893/4885LMNA 1322/4885RAB9A 2571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.